AVTX

Avalo Therapeutics, Inc. (AVTX) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company's lead asset is abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody. The filing notes that positive topline data was recently reported for abdakibart in a Phase 2 clinical trial for hidradenitis suppurativa (HS).

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose by $6.2 million (42%) year-over-year. R&D expenses increased by $4.9 million, driven by higher clinical expenses ($1.8M increase) and Chemistry, Manufacturing, and Controls (CMC) expenses ($2.1M increase) related to the LOTUS trial and preparations for pivotal Phase 3 trials. G&A expenses increased by $1.3 million due to headcount additions and higher stock-based compensation.
• Net Loss Expansion: Net loss increased by $6.5 million compared to Q1 2025, primarily due to higher operating costs, partially offset by a decrease in interest income.
• Investment Activity: The company generated $25.5 million in net cash from investing activities in Q1 2026 through the sale and maturity of investments, compared to zero in the prior year period.
• Derivative Liability: The fair value of the derivative liability increased to $17.5 million from $8.1 million in the prior year, driven by updated sales forecasts and probability of success for out-licensed assets (specifically AVTX-007).

Guidance, Outlook, and Recent Developments

• Phase 2 LOTUS Trial Success: On May 5, 2026, the company announced positive topline results for the Phase 2 LOTUS trial in HS. The trial met its primary endpoint at both doses studied, demonstrating statistically significant improvement in HiSCR75 response rates. Management plans to advance abdakibart into a registrational Phase 3 program.
• Capital Raise (Subsequent Event): On May 7, 2026, Avalo completed a follow-on offering of common stock and pre-funded warrants. The company sold approximately 22.9 million shares and 1.4 million pre-funded warrants at $17.75 per share. Gross proceeds were approximately $431.3 million, with net proceeds expected to be approximately $405.0 million.
• Liquidity Outlook: Management expects that existing cash, cash equivalents, short-term investments, and the net proceeds from the May 2026 offering are sufficient to fund operations for at least twelve months from the filing date and into 2029.
• Milestone Buyout Agreement: In April 2026, the company entered into an agreement to pay $2.25 million upfront for an option to pay an additional $5.125 million in lieu of a $15.0 million contingent milestone payment to former AlmataBio stockholders upon the first patient dosing in a Phase 3 trial.
• Risks: The company remains dependent on successful clinical trials and regulatory approvals. Future funding may require additional equity issuances, which could dilute existing shareholders. The company also faces risks related to the valuation of derivative liabilities and the success of out-licensed programs.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $405 million net proceeds from the May 2026 offering to fund the planned Phase 3 program and operations through 2029.
• Phase 3 Timeline: Confirm the projected timeline and budget for initiating the registrational Phase 3 trial for abdakibart following the positive Phase 2 data.
• Dilution Impact: Assess the impact of the May 2026 offering (22.9 million shares + 1.4 million warrants) on existing shareholder ownership and earnings per share.
• Derivative Liability Volatility: Monitor the fair value of the $17.5 million derivative liability, which is sensitive to sales forecasts and probability of success for out-licensed assets (AVTX-007).
• Milestone Obligations: Track the status of the $10.0 million milestone payable to Eli Lilly (determined probable in May 2026) and the potential exercise of the $5.125 million buyout option for the AlmataBio Phase 3 milestone.